HSANZ Free Communications 5: Aggressive Lymphoma
Tracks
HSANZ
| Tuesday, November 7, 2023 |
| 8:30 AM - 10:00 AM |
| Plenary 3 |
Details
Kindly sponsored by Roche Products Limited
Speaker
Dr Stephen Boyle
Haematologist
King's College Hospital, London
Improvement in CAR-T outcomes over time – lessons from the UK experience
8:30 AM - 8:45 AMBiography
Stephen is an early-career haematologist based in Brisbane, having recently returned from a 1-year CAR-T fellowship in one of Europe's largest CAR-T centres, King's College Hospital London. He is undertaking a PhD developing novel myeloma CAR-T therapy in Brisbane and has published and presented nationally and internationally on lymphoma CAR-T.
Dr Mark Dowling
Haematologist
Peter MacCallum Cancer Centre
Single-institution outcomes of standard-of-care chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in third-line or beyond: an Australian real-world experience
8:45 AM - 9:00 AMBiography
Mark is a clinical haematologist and Victorian Cancer Agency mid-career research fellow at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital.
Dr Victor Lin
Medical Registrar
Royal Melbourne Hospital
Real-world outcomes of patients with double-hit lymphoma treated from 2013 to 2023 at Royal Melbourne Hospital and Peter MacCallum Cancer Centre
9:00 AM - 9:15 AMBiography
Victor Lin is a medical registrar at the Royal Melbourne Hospital and clinical researcher at Peter MacCallum Cancer Centre. Victor has a keen interest in all aspects of haematology, but especially blood cancers. He has published in several high-impact journals, including Blood, and presented at multiple national and international conferences.
Dr Michael Dickinson
Haematologist
Peter MacCallum Cancer Centre / Royal Melbourne Hospital / University of Melbourne
Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma
9:15 AM - 9:30 AMBiography
Michael Dickinson is Lead of Aggressive Lymphoma at Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Associate Professor at the University of Melbourne, and is a lead investigator in the glofitamab program.
Dr Michael Dickinson
Haematologist
Peter MacCallum Cancer Centre / Royal Melbourne Hospital / University of Melbourne
Glofitamab monotherapy in patients with relapsed/refractory Large B-Cell Lymphoma: Extended follow-up and landmark analyses from pivotal phase II study
9:30 AM - 9:45 AMBiography
Michael is the Lead of Aggressive Lymphoma at Peter MacCallum Cancer Centre and Royal Melbourne Hospital, and is the lead investigator in the pivotal global trial of glofitamab in DLBCL.
Dr Robin Gasiorowski
Haematologist
Concord Hospital / The University of Sydney
Epcoritamab SC induces durable complete remissions in patients with relapsed/refractory diffuse large B-cell lymphoma: long-term results of EPCORE NHL 1
9:45 AM - 10:00 AMBiography
Dr Gasiorowski received medical training at Cambridge University and University College London, haematology specialist training at Royal Prince Alfred and Concord hospitals, and a PhD at the University of Sydney. He is a clinical and laboratory haematologist at Concord and Macquarie University Hospitals and conducts trials in lymphoma and leukaemia.
Chairperson
Allison Barraclough
Haematologist
Fiona Stanley Hospital
William Renwick
Consultant Haematologist
Western Health
